Our Pricing

Do You Have to Increase Wegovy vs Mounjaro Dose? UK Titration Schedules Compared

Understanding Wegovy vs Mounjaro dose increase requirements is essential for anyone starting GLP-1 weight loss therapy in the UK. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) require gradual dose escalation to minimise gastrointestinal side effects and optimise tolerability, but their titration schedules, flexibility, and maintenance dose options differ significantly. This guide explains the clinical rationale behind mandatory dose progression, compares both medications' escalation pathways, and clarifies when staying at a lower dose may be appropriate under prescriber guidance.

Why Wegovy vs Mounjaro Dose Increase Is Medically Necessary

Both Wegovy and Mounjaro require dose escalation because abrupt introduction at therapeutic levels causes unacceptable gastrointestinal adverse events in most patients [1]. The gradual titration approach used in the STEP trials for semaglutide and SURMOUNT trials for tirzepatide demonstrated that stepwise increases every four weeks significantly improved treatment adherence and reduced discontinuation rates compared to faster escalation protocols.

GLP-1 receptor agonists like semaglutide slow gastric emptying and enhance satiety signalling, effects that intensify with higher doses. Starting at the lowest dose (0.25mg for Wegovy, 2.5mg for Mounjaro) allows the gastrointestinal system to adapt progressively, reducing nausea, vomiting, and diarrhoea incidence by 40-60% compared to immediate therapeutic dosing [2]. This physiological adaptation period is not optional—it's a core component of safe prescribing protocols approved by the MHRA.

Clinical guidelines from NICE emphasise that dose titration must follow the licensed schedule unless a prescriber documents specific contraindications or intolerable side effects. Skipping titration steps or accelerating the schedule increases the risk of treatment discontinuation and does not improve weight loss outcomes. Patients who attempt to bypass gradual escalation typically experience severe nausea that forces treatment interruption, ultimately delaying progress toward therapeutic doses.

Wegovy vs Mounjaro Dose Increase Schedules: Key Differences

Wegovy follows a five-step titration over 16-20 weeks: 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, and finally 2.4mg maintenance dose [3]. Each increment occurs monthly, allowing four weeks of physiological adaptation before progression. The STEP 1 trial demonstrated that this schedule achieved 14.9% average body weight reduction at 68 weeks with 2.4mg maintenance dosing, with only 4.5% discontinuation due to gastrointestinal events.

Mounjaro uses a four-step escalation over 12-16 weeks: 2.5mg weekly for four weeks, then 5mg, 7.5mg (optional intermediate), 10mg, 12.5mg, and up to 15mg maximum [4]. Tirzepatide's dual GIP/GLP-1 mechanism may offer slightly better tolerability during titration, with SURMOUNT-1 showing 15.0% weight reduction at 72 weeks with 5mg dosing and 20.9% with 15mg. Importantly, many patients achieve substantial weight loss at 10mg or even 5mg, potentially avoiding higher doses entirely.

The critical difference: Wegovy has one standard maintenance dose (2.4mg), while Mounjaro offers three potential maintenance options (10mg, 12.5mg, 15mg) based on individual response and tolerability. This flexibility means some Mounjaro patients may not need to increase beyond 10mg if weight loss goals are met, whereas Wegovy patients typically progress to the full 2.4mg unless side effects prevent it. Both medications require prescriber approval for any deviation from standard titration.

Can You Stay at a Lower Wegovy vs Mounjaro Dose Permanently?

Staying at a sub-therapeutic dose is possible under prescriber supervision if you've achieved your weight loss target or experience intolerable side effects at higher doses. For Wegovy, some patients maintain 1mg or 1.7mg long-term if they've reached 5-10% body weight reduction and further escalation causes persistent nausea. However, clinical trial data shows maximal efficacy at 2.4mg, so prescribers typically encourage progression unless contraindicated [5].

Mounjaro's multiple maintenance options provide more flexibility—patients achieving 10-15% weight loss at 5mg or 10mg may not require further dose increase. The SURMOUNT trials demonstrated clinically significant outcomes across all dose levels, with 5mg producing comparable results to Wegovy 2.4mg in some subgroups. Your prescriber will assess weight trajectory, tolerability, and metabolic markers every 8-12 weeks to determine whether dose escalation remains necessary or whether a lower maintenance dose is appropriate for your individual response.

Side Effects During Wegovy vs Mounjaro Dose Increase Phases

Gastrointestinal adverse events peak during the first 2-3 weeks after each dose escalation, then typically subside as tolerance develops. Nausea affects 40-50% of patients during Wegovy titration and 30-40% during Mounjaro escalation, but severe nausea requiring dose reduction occurs in fewer than 8% of cases when titration schedules are followed correctly [6]. Vomiting, diarrhoea, constipation, and abdominal discomfort follow similar patterns, with intensity correlating to dose magnitude rather than medication type.

Tirzepatide's dual agonist mechanism may confer slightly better gastrointestinal tolerability during dose increases compared to pure GLP-1 agonists like semaglutide, though head-to-head trials are limited. Anecdotal clinical experience suggests Mounjaro patients report less severe nausea at equivalent weight loss efficacy, potentially due to GIP receptor modulation of gastric motility. However, individual variation is substantial—some patients tolerate Wegovy escalation perfectly while struggling with Mounjaro, and vice versa.

Managing side effects during titration involves eating smaller portions, avoiding high-fat meals, staying hydrated, and timing injections consistently. If nausea persists beyond three weeks at a new dose, contact your prescriber—they may extend the current dose for another four weeks before escalating, or prescribe anti-emetics like domperidone short-term. Never skip doses or delay injections to avoid side effects, as this disrupts the titration schedule and worsens tolerability when you resume.

Wegovy vs Mounjaro Dose Increase Costs Across UK Pharmacies

At Cured Pharmacy, Wegovy starts from £124.99 and Mounjaro from £124.99, with transparent per-pen pricing displayed before your clinical assessment. These prices apply regardless of dose strength, meaning your cost remains consistent throughout titration—whether you're on the 0.25mg starter dose or 2.4mg maintenance. Many UK pharmacies charge variable pricing based on dose tier, making long-term budgeting difficult as you progress through escalation phases.

New patients receive £20 off their first order with code Weightlossnew, reducing initial costs to £124.99 for Wegovy or £124.99 for Mounjaro. This discount applies to any dose strength, allowing you to trial the medication at the lowest financial barrier. Cured Pharmacy guarantees the cheapest UK price for both medications, with no hidden consultation fees or administration charges—the price you see includes prescriber assessment, medication, and discreet home delivery within 24-48 hours.

Over a typical 6-month titration and maintenance period, Wegovy costs approximately £124.99 (six monthly pens at £124.99 each, minus £124.99 first-order discount), while Mounjaro costs approximately £124.99 (six pens at £124.99 minus £124.99). However, if you achieve target weight loss at a lower Mounjaro dose like 5mg or 10mg and maintain that dose long-term, overall costs may align more closely. Your prescriber will discuss cost-effectiveness alongside clinical outcomes during follow-up assessments to optimise both health and budget considerations.

Does Insurance or NHS Cover Wegovy vs Mounjaro Dose Escalation?

NHS prescription of Wegovy or Mounjaro remains highly restricted in 2025, limited to specialist weight management services for patients with BMI ≥35 plus comorbidities or BMI ≥30 with specific conditions. Even when NHS-prescribed, you'll follow the same mandatory titration schedule—dose escalation is a clinical requirement, not a cost-saving measure, so neither the NHS nor private insurers alter the progression pathway.

Private health insurance rarely covers weight loss medications in the UK, as most policies exclude lifestyle or cosmetic treatments. If your policy does provide obesity medication coverage, pre-authorisation typically requires documented failed attempts at diet and exercise, BMI criteria, and agreement to follow the licensed titration schedule. Cured Pharmacy provides detailed invoices and prescription documentation that you can submit for potential reimbursement, though approval rates remain low across UK insurers.

What Happens If You Miss a Wegovy vs Mounjaro Dose Increase?

Missing a single weekly injection during titration delays your escalation schedule but doesn't require restarting from the beginning. If you miss a Wegovy or Mounjaro dose and remember within five days, administer it immediately and resume your normal weekly schedule. If more than five days have passed, skip the missed dose and continue with your next planned injection—do not double-dose to compensate [7].

Missing multiple consecutive doses (two weeks or more) may require restarting titration at a lower dose to re-establish tolerance. Your prescriber will assess how long you've been off treatment and your previous highest tolerated dose to determine the appropriate restart point. Patients who achieved 1.7mg Wegovy or 10mg Mounjaro before interruption typically restart one or two steps lower rather than returning to the initial 0.25mg or 2.5mg starter dose.

Interrupting treatment during dose escalation increases the risk of regaining lost weight, as GLP-1 medications suppress appetite only while active in your system. The STEP 4 trial demonstrated that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year [8]. If you anticipate treatment interruption due to travel, surgery, or financial constraints, discuss maintenance strategies with your prescriber—sometimes staying at your current dose is preferable to complete cessation followed by titration restart.

Wegovy vs Mounjaro Dose Increase: Which Offers Better Flexibility?

Mounjaro provides superior dose flexibility due to its multiple maintenance options (5mg, 10mg, 12.5mg, 15mg) and demonstrated efficacy across the dose range. Patients who achieve 10-15% weight loss at 5mg or 10mg can maintain that dose indefinitely under prescriber guidance, avoiding unnecessary escalation and higher costs. This flexibility particularly benefits patients with moderate weight loss goals (10-15kg) or those experiencing tolerable but bothersome side effects at higher doses.

Wegovy's single 2.4mg maintenance dose offers less flexibility but simplifies treatment—there's no ambiguity about target dosing, and clinical trial data overwhelmingly supports 2.4mg as the optimal therapeutic dose. Patients who cannot tolerate 2.4mg typically maintain 1mg or 1.7mg, but these lower doses weren't the primary endpoints in STEP trials, so long-term efficacy data is less robust. Prescribers may prefer Wegovy for patients who need clear, unambiguous dosing protocols without ongoing titration decisions.

Your choice between Wegovy vs Mounjaro dose increase schedules should consider your weight loss target, side effect sensitivity, budget, and preference for dosing simplicity versus flexibility. Both medications require gradual escalation—neither allows skipping titration—but Mounjaro's multiple maintenance options may suit patients seeking individualised dosing, while Wegovy's straightforward progression appeals to those preferring a defined treatment pathway. Cured Pharmacy's clinical team assesses your medical history, previous weight loss attempts, and personal preferences during your online consultation to recommend the most appropriate medication and prepare you for the titration journey ahead.

Can You Switch Between Wegovy and Mounjaro Mid-Titration?

Switching from Wegovy to Mounjaro (or vice versa) mid-titration is possible under prescriber supervision, though it requires careful dose equivalency assessment. Approximate equivalence suggests Wegovy 1mg corresponds to Mounjaro 5mg, and Wegovy 2.4mg to Mounjaro 10-12.5mg based on weight loss outcomes, but individual response varies. Your prescriber will consider your current dose, tolerability, weight loss trajectory, and reasons for switching before recommending a starting dose on the new medication.

Most patients switching medications don't restart at the absolute lowest dose—if you've tolerated Wegovy 1mg for eight weeks, you might begin Mounjaro at 5mg rather than 2.5mg, though conservative prescribers may still initiate at 2.5mg for one month to assess cross-tolerance. Switching typically occurs due to inadequate weight loss response, intolerable side effects, supply shortages, or cost considerations. Cured Pharmacy's prescribers provide detailed switching protocols and close monitoring during transition periods to minimise side effects and maintain weight loss momentum.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
4. Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA, 325(14), 1403-1413. [accessed 15 August 2026]
5. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
6. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2021). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 15 August 2026]
7. Novo Nordisk. (2023). Wegovy (semaglutide) prescribing information. Electronic Medicines Compendium. [accessed 15 August 2026]
8. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.